<DOC>
	<DOC>NCT01081873</DOC>
	<brief_summary>Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOTÂ® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the Belgian marketing authorization and reimbursement conditions.</brief_summary>
	<brief_title>Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Patients with advanced prostate cancer who have been prescribed Lucrin/ LucrinTridepot or any other treatment with local reimbursement guidelines; Patients willing to consent to data being collected and provided to Abbott Laboratories. Contraindications according to the Summary of Product Characteristics (SPC).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Multicenter study</keyword>
</DOC>